Generate Biomedicines (NASDAQ:GENB) Shares Break Above 200 Day Moving Average - Here's Why

Key Points

• Generate Biomedicines shares broke above their 200-day moving average, reaching $15.39 and closing near $15.38 on trading volume of approximately 3.9 million shares.
• Analyst sentiment is mixed but leans positive: six analysts rate the stock a Buy, one a Hold and one a Sell, producing a “Moderate Buy” consensus and an average price target of $26.40.
• The company reported a quarterly loss of $0.52 per share, missing estimates by $0.04, while several institutional investors recently established or increased positions in GENB.

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $14.15 and traded as high as $15.39. Generate Biomedicines shares last traded at $15.38, with a volume of 3,927,640 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on GENB shares. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Generate Biomedicines in a research report on Monday, October 5th. Weiss Ratings upgraded Generate Biomedicines from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 25th. Finally, Wall Street Zen lowered Generate Biomedicines from a "hold" rating to a "sell" rating in a research report on Saturday, October 17th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $26.40.

Generate Biomedicines Price Performance

The stock has a market capitalization of $1.97 billion and a price-to-earnings ratio of -9.67. The business has a 50 day simple moving average of $15.05 and a 200-day simple moving average of $14.15.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter. As a group, equities analysts predict that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.

Institutional Trading of Generate Biomedicines

A number of large investors have recently bought and sold shares of GENB. Susquehanna International Group LLP acquired a new position in Generate Biomedicines in the 2nd quarter worth $196,000. AXQ Capital LP acquired a new stake in shares of Generate Biomedicines in the 2nd quarter valued at about $218,000. Magnus Financial Group LLC raised its stake in shares of Generate Biomedicines by 39.4% in the 3rd quarter. Magnus Financial Group LLC now owns 21,750 shares of the company's stock valued at $327,000 after purchasing an additional 6,150 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Generate Biomedicines in the second quarter valued at about $530,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Generate Biomedicines in the second quarter valued at about $967,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence, machine learning and protein engineering to design novel protein-based medicines. Its platform is intended to identify and develop therapeutic proteins with desired biological properties, potentially shortening the time required to discover new drug candidates.

The company's research activities focus on applying computational biology and laboratory experimentation to create medicines for a range of diseases, including conditions in immunology, inflammation, oncology and other areas of significant unmet medical need.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.